NCT06868082

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and Non-Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Uniquity One (UNI) · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	Solrikitug	Solrikitug Formulation 1
BIOLOGICAL	Solrikitug	Solrikitug Formulation 2

Timeline

• Start date: 2025-06-20
• Primary completion: 2026-02-02
• Completion: 2026-02-02
• First posted: 2025-03-10
• Last updated: 2026-02-09

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study